Last reviewed · How we verify

NCT03765749

Empirical Antibiotic and Outcome in Community-onset Bacteremia

Completed Last updated 19 April 2022
What this trial tests

trial in Bacteremia in 108 participants. Completed in 31 December 2021.

Timeline
22 November 2018
Primary endpoint
31 December 2021
31 December 2021

Quick facts

Lead sponsorPhramongkutklao College of Medicine and Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment108
Start date22 November 2018
Primary completion31 December 2021
Estimated completion31 December 2021
Sites1 location across Thailand

Conditions studied

Sponsor

Phramongkutklao College of Medicine and Hospital

Who can join

18 and older, any sex, with Bacteremia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Empirical antibiotic and outcome in Community-onset Bacteremia Caused by third generation cephalosporin resistant Enterobacteriaceae

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Impact of Inappropriate Empirical Antibiotic on Outcomes in Community-acquired Third Generation Cephalosporin Resistant <i>Enterobacterales</i> Bacteremia.
    Nasomsong W, Changpradub D, Vasikasin V. · · 2022 · cited 3× · PMID 36596682 · DOI 10.3947/ic.2022.0096

Verify or expand the search:

Other recruiting trials for Bacteremia

Currently open trials in the same condition.

Other Phramongkutklao College of Medicine and Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03765749.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing